CA
NZ
UK
AU
IND
US
…
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC). The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Galera Therapeutics Inc is a publicly traded biopharmaceutical company on OTCQB with limited public disclosures. Long-term growth may depend on advancing any development-stage programs, achieving regulatory milestones, securing partnerships and maintaining capital to support commercialization. Investors may find exposure to potential high-reward biotech outcomes appealing if management delivers on key milestones.
Principal risks are limited public information, clinical and regulatory setbacks typical of early-stage biotech, financing and dilution risk, and low liquidity associated with an OTCQB listing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 149.05M | -19.16M | -59.08M | -62.29M | -80.53M |
| Net income | 149.05M | -18.96M | -59.08M | -62.22M | -87.73M |
| Selling general administrative | 5.69M | 11.00M | 22.84M | 20.21M | 20.95M |
| Selling and marketing expenses | - | - | 0.26M | - | - |
| Gross profit | - | -3.84M | -0.26M | - | - |
| Reconciled depreciation | 0.00M | 0.02M | 0.07M | 0.11M | 0.78M |
| Ebit | - | - | -46.95M | -51.34M | -73.37M |
| Ebitda | - | -20.16M | -46.69M | -51.23M | -72.56M |
| Depreciation and amortization | - | - | 0.26M | 0.11M | 0.81M |
| Non operating income net other | - | - | - | 0.51M | - |
| Operating income | -6.04M | -20.16M | -46.95M | -51.23M | -73.37M |
| Other operating expenses | - | 18.00M | 46.95M | 51.23M | 73.37M |
| Interest expense | - | 0.00M | 11.41M | 11.57M | 7.19M |
| Tax provision | 0.00M | -0.20M | 0.00M | -0.07M | 0.00M |
| Interest income | 0.25M | 0.55M | 1.55M | 0.51M | 0.03M |
| Net interest income | 0.25M | 0.55M | -12.48M | -11.06M | -7.16M |
| Income tax expense | - | -0.20M | - | -0.07M | 7.19M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 6.04M | 14.15M | 46.69M | 51.23M | 73.37M |
| Cost of revenue | - | 3.84M | 0.26M | - | - |
| Total other income expense net | 154.84M | 1.00M | -12.13M | -11.07M | -7.17M |
| Net income from continuing ops | 149.05M | -18.96M | -69.68M | -62.36M | -80.53M |
| Net income applicable to common shares | - | - | - | -62.22M | -80.53M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 7.20M | 10.10M | 26.14M | 44.04M | 83.31M |
| Intangible assets | - | - | 2.26M | 2.26M | 2.26M |
| Other current assets | 0.23M | 1.08M | 3.37M | 6.89M | 6.17M |
| Total liab | 0.65M | 153.77M | 157.33M | 153.22M | 141.31M |
| Total stockholder equity | 6.55M | -143.67M | -131.19M | -109.18M | -58.00M |
| Other current liab | - | 0.39M | 3.45M | 9.75M | 7.63M |
| Common stock | - | 0.07M | 0.05M | 0.03M | 0.03M |
| Capital stock | 2.65M | 4.45M | 0.05M | 0.03M | 0.03M |
| Retained earnings | -307.31M | -456.36M | -437.41M | -378.32M | -316.10M |
| Other liab | - | - | - | 0.20M | 128.34M |
| Good will | - | 0.00M | 0.88M | 0.88M | 0.88M |
| Other assets | - | - | 0.00M | 1.88M | 1.96M |
| Cash | 6.38M | 8.29M | 18.26M | 4.27M | 19.86M |
| Total current liabilities | 0.65M | 1.67M | 4.96M | 13.38M | 12.94M |
| Net debt | - | -8.29M | 134.04M | -4.22M | -19.56M |
| Short term debt | - | - | 0.13M | 0.04M | 0.26M |
| Short long term debt total | - | - | 152.30M | 0.04M | 0.30M |
| Other stockholder equity | - | 308.25M | 306.17M | 269.14M | 258.09M |
| Property plant equipment | - | - | - | 0.44M | 0.82M |
| Total current assets | 7.09M | 10.00M | 21.63M | 38.53M | 77.39M |
| Net tangible assets | - | - | - | -112.32M | -61.14M |
| Short term investments | - | - | 0.00M | 27.33M | 51.36M |
| Net receivables | - | 0.64M | - | 3.24M | - |
| Accounts payable | 0.27M | 1.27M | 1.38M | 3.58M | 5.04M |
| Accumulated other comprehensive income | - | - | 0.00M | -0.02M | -0.01M |
| Common stock total equity | - | - | - | 0.03M | - |
| Retained earnings total equity | - | - | - | -378.32M | - |
| Non currrent assets other | 0.10M | 0.10M | 0.09M | 1.88M | 1.96M |
| Non current assets total | 0.10M | 0.10M | 4.51M | 5.50M | 5.92M |
| Capital lease obligations | - | 0.00M | 1.25M | 0.04M | 0.30M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.05M | 26.10M | 24.02M | 5.52M |
| Change to liabilities | - | - | - | 0.66M | -0.10M |
| Total cashflows from investing activities | - | - | - | 23.99M | 5.24M |
| Net borrowings | - | - | - | - | 57.50M |
| Total cash from financing activities | 0.64M | 2.22M | 31.50M | 3.89M | 66.71M |
| Change to operating activities | - | - | - | 1.48M | -2.53M |
| Net income | 149.05M | -18.96M | -59.08M | -62.22M | -80.53M |
| Change in cash | -1.91M | -9.97M | 13.94M | -15.54M | 3.99M |
| Begin period cash flow | 8.29M | 18.26M | 4.32M | 19.86M | 15.87M |
| End period cash flow | 6.38M | 8.29M | 18.26M | 4.32M | 19.86M |
| Total cash from operating activities | -6.05M | -12.14M | -44.85M | -43.43M | -67.96M |
| Issuance of capital stock | 0.64M | 2.22M | 32.22M | 3.81M | 7.94M |
| Depreciation | 0.00M | 0.02M | 0.26M | 0.11M | 0.78M |
| Other cashflows from investing activities | - | 0.00M | - | - | - |
| Change to account receivables | - | - | -0.10M | - | - |
| Sale purchase of stock | - | - | - | 3.89M | - |
| Other cashflows from financing activities | - | 2.22M | 2.20M | 0.08M | 58.77M |
| Change to netincome | - | - | - | 18.66M | 14.43M |
| Capital expenditures | 0.00M | 0.00M | 0.06M | 0.03M | 0.28M |
| Cash flows other operating | - | - | - | -0.64M | - |
| Cash and cash equivalents changes | - | - | - | -15.54M | - |
| Change in working capital | -0.67M | -2.13M | -2.93M | 0.02M | -2.63M |
| Stock based compensation | 0.41M | 2.54M | 5.56M | 7.16M | 7.23M |
| Other non cash items | - | 6.58M | 11.34M | 11.57M | 7.19M |
| Free cash flow | -6.05M | -12.14M | -44.91M | -43.45M | -68.24M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.24 0.61% |
40.20 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-21.28 3.85% |
531.87 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
12.10 1.26% |
973.36 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC). The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
| Name | Title | Year Born |
|---|---|---|
| Dr. J. Mel Sorensen M.D. | CEO, Pres & Director | 1957 |
| Mr. Christopher Degnan | Chief Financial Officer | 1980 |
| Mr. Mark J. Bachleda M.B.A., Pharm.D. | Chief Commercial Officer | 1975 |
| Dr. Robert A. Beardsley M.B.A., Ph.D. | Co-Founder & COO | 1962 |
| Dr. Dennis P. Riley Ph.D. | Chief Scientific Officer, Emeritus | NA |
| Ms. Jennifer Evans Stacey Esq. | Chief Legal & Compliance Officer and Sec. | 1965 |
| Dr. Jon T. Holmlund M.D. | Exec. Officer | 1957 |
| Ms. Andie Collier | Sr. VP of Regulatory Affairs | NA |
| Ms. Judy Schnyder | Sr. VP of Clinical Operations & Data Management | NA |
| Dr. Eugene P. Kennedy F.A.C.S., FACS, M.D. | Chief Medical Officer | 1969 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.39%
Communication Services
+0.40%
Consumer Cyclical
-0.20%
Consumer Defensive
-0.56%
Energy
-0.45%
Financial Services
-0.09%
Financials
+0.11%
Healthcare
+0.40%
Industrials
+0.34%
Real Estate
-0.14%
Technology
+0.88%
Utilities
+0.11%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...